Stockman Wealth Management Inc. Buys 2,583 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Share on StockTwits

Stockman Wealth Management Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,394 shares of the biopharmaceutical company’s stock after acquiring an additional 2,583 shares during the period. Gilead Sciences comprises 1.6% of Stockman Wealth Management Inc.’s holdings, making the stock its 21st largest holding. Stockman Wealth Management Inc.’s holdings in Gilead Sciences were worth $4,013,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisors Preferred LLC bought a new position in shares of Gilead Sciences during the second quarter valued at $26,000. Weaver Consulting Group bought a new position in Gilead Sciences during the first quarter worth $34,000. Trustcore Financial Services LLC bought a new position in Gilead Sciences during the first quarter worth $34,000. Legacy Advisors LLC bought a new position in Gilead Sciences during the second quarter worth $37,000. Finally, Evolution Wealth Advisors LLC bought a new position in Gilead Sciences during the second quarter worth $46,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Shares of NASDAQ GILD traded up $0.28 during midday trading on Tuesday, hitting $63.28. The company’s stock had a trading volume of 235,280 shares, compared to its average volume of 6,278,891. The stock has a fifty day moving average price of $65.17 and a 200 day moving average price of $65.64. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $79.17 billion, a price-to-earnings ratio of 10.30, a P/E/G ratio of 2.97 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.54 billion. During the same quarter in the previous year, the firm posted $1.91 earnings per share. The company’s quarterly revenue was down 2.8% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post 6.65 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

In related news, EVP Brett A. Pletcher sold 608 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,750,191.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the sale, the executive vice president now directly owns 34,398 shares in the company, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Insiders have sold a total of 13,624 shares of company stock worth $907,479 in the last ninety days. 0.20% of the stock is currently owned by insiders.

A number of brokerages recently weighed in on GILD. Goldman Sachs Group downgraded shares of Gilead Sciences from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $70.00 to $60.00 in a research note on Tuesday, May 28th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, July 15th. BMO Capital Markets set a $82.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 31st. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, June 5th. Finally, Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Monday, July 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $82.24.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What is Blockchain?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.